elive™

Evaluate IO therapy response before treatment begins

Use your patient's live tumor biopsy to guide personalized therapy selection with elive.

elive is a Laboratory Developed Test (LDT) that uses cytokine profiling from a fresh core needle biopsy (CNB) to predict a patient's likelihood of response to a specific immune checkpoint inhibitor. Unlike other tests, elive:

- **Preserves** the functional, live tumor microenvironment
- **Assesses** inducible immune response from cytokines commonly associated with T-cell activation
- **Provides** actionable results within 14 days of biopsy
- **Requires** only a single CNB for analysis

Go beyond the limitations of current immunotherapy biomarkers.

elive changes the way providers and patients are making treatment decisions.

How it works:

- A patient biopsy is collected, and the live sample is shipped overnight to Elephas Laboratories using our temperature controlled collection kit
- Our CLIA-certified laboratory uses the Elephas Live™ Platform to evaluate immune activation following exposure to ICI treatment
- Each unique response profile is analyzed in-house, and assessed for response thresholds based on Elephas clinical datasets
- Patient report is issued to provider with tumor response profile and pathologist interpretation within 14 days

Patient Profile

elive is intended for patients with suspected or confirmed solid tumor, who are also candidates for IO therapy and eligible for evaluation by means of biopsy.

A 12- to 20-gauge, fresh core needle biopsy of 10mm or more in length is required for testing.

Availability:

The elive test is available through Elephas Laboratories starting January 2026 in a limited use.

Phone: (608) 622-7954
Email: elive@elephaslabs.com
Find us online: www.elephaslabs.com

elephas®
LABORATORIES

Changing the way your patients receive immunotherapy

Elephas Laboratories
1 Erdman Pl, Suite 100, Madison, WI 53717, United States